Acute myeloid leukaemia (AML) trials
- IDH1 inhibitor study for adults with AML with IDH1 mutation, either relapsed or refractory to conventional treatment or for those unsuitable for conventional treatment at presentation.
- Trial of MDM2 antagonist in combination with low intensity chemotherapy for relapsed/refractory AML with wild type TP53 in adults
- AML19 for untreated patients aged 18-60 years with AML. Looking at the combination of gemtuzumab ozogamicin and midostaurin in combination with standard chemotherapy
- AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
Acute lymphoblastic leukaemia (ALL) trials
- UKALL2011 trial for young adults aged 18-24 years with untreated ALL, looking at different doses of steroids and high dose methotrexate
- MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults.
- Daratumumab plus chemotherapy for first relapsed/refractory T acute lymphoblastic leukaemia in young adults (<30 years)
Chronic lymphoid leukaemias
- Randomised clinical trial comparing R-FC to R-Ibrutinib in treatment naïve CLL patients with intact TP53
- Randomised clinical trial comparing Ibrutinib to Acalabrutinib in patients with previously treated CLL with ATM or TP53 loss
- A dose-finding study of single agent idelalisib in the treatment of double-refractory follicular lymphoma
- A clinical trial of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory DL
Myelodysplastic syndromes and other myeloid disorders
For patients with low blood counts of uncertain cause we have a gene sequencing study to test whether any genes are mutated.
Academic and commercial trials are run through the Haemato-oncology Unit. Trials that are currently recruiting are listed below under each disease category.
Please email us for more information about our haemato-oncology clinical trials.